Skip to main content

Drug Interactions between mumps skin test antigen and umbralisib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

mumps skin test antigen umbralisib

Applies to: mumps skin test antigen and umbralisib

MONITOR: Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.

MANAGEMENT: Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.

References

  1. (2001) "Product Information. Candin (candida albicans extract)." Nielsen Biosciences Inc
  2. (2001) "Product Information. Histolyn-Cyl (histoplasmin)." ALK Laboratories Inc
  3. (2001) "Product Information. Spherulin (coccidioidin skin test)." ALK Laboratories Inc
  4. (2001) "Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen)." Aventis Pharmaceuticals
  5. (2001) "Product Information. Multitest CMI (skin test antigens, multiple)." Aventis Pharmaceuticals
  6. "Product Information. Tuberculin Tine Test (tuberculin purified protein derivative)." Connaught Laboratories Inc
View all 6 references

Switch to consumer interaction data

Drug and food interactions

Moderate

umbralisib food

Applies to: umbralisib

ADJUST DOSING INTERVAL: Food enhances the oral bioavailability of umbralisib. When a single oral dose of umbralisib was administered with a high-fat, high-calorie meal (approximately 917 calories; 171 calories from protein, 232 calories from carbohydrate, 502 calories from fat) in healthy subjects, umbralisib peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 115% and 61%, respectively, compared to administration under fasted conditions.

MANAGEMENT: Umbralisib should be administered with food at approximately the same time each day.

References

  1. "Multum Information Services, Inc. Expert Review Panel"

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer